Intratumoral PH-762 for Cutaneous Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT06014086|
Recruitment Status : Recruiting
First Posted : August 28, 2023
Last Update Posted : November 9, 2023
|Condition or disease||Intervention/treatment||Phase|
|Squamous Cell Carcinoma of the Skin Malignant Melanoma of Skin Merkel Cell Carcinoma of Skin||Drug: PH-762||Phase 1|
PH-762 is a potent RNAi molecule targeting PD-1. PH-762 can inhibit the immune checkpoint PD-1 in the tumor and thereby impede tumor growth. As a preoperative therapy, it may decrease the lesion size and has the potential to improve surgical morbidity. Intratumoral immunotherapy aims to use the tumor as a 'self-vaccine'. The local immune stimulation can induce robust priming of an anti-tumor immune response while generating systemic (abscopal) tumor responses, mediated by properly activated anti-tumor immune cells in the circulation. Local delivery of immunotherapy is expected to minimize systemic exposure and off-target toxicities.
This is a non-comparative study of neoadjuvant monotherapy using PD-1 targeting self-delivering RNAi (PH-762) in adult subjects with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The study treatment consists of four intratumoral injections of PH-762 at weekly intervals, into a single tumor lesion. Excision of the tumor will occur approximately two weeks following the fourth dose of IT PH-762, and the subjects will be followed for an additional 11 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Dose Escalation Study of Neoadjuvant Intratumoral PH-762 for Cutaneous Squamous Cell Carcinoma, Melanoma, or Merkel Cell Carcinoma|
|Actual Study Start Date :||November 7, 2023|
|Estimated Primary Completion Date :||June 2025|
|Estimated Study Completion Date :||September 2025|
Experimental: Sequential escalating doses of PH-762.
Escalating doses of PH-762 are to be tested, with an observation period between doses.
PH-762 is a potent RNAi molecule targeting PD-1.
- Adverse Events [ Time Frame: 16 weeks ]Incidence, severity, seriousness and relatedness of all treatment-emergent adverse events.
- Pharmacokinetics: maximum plasma concentration (Cmax) [ Time Frame: 3.5 weeks ]Maximum concentration of PH-762 following intratumoral injection.
- Pharmacokinetics: time to maximum plasma concentration (Tmax) [ Time Frame: 3.5 weeks ]Time to maximum concentration of PH-762 following intratumoral injection.
- Pharmacokinetics: area under the curve to last quantifiable plasma concentration (AUClast) [ Time Frame: 3.5 weeks ]Exposure to PH-762 through last quantifiable concentration following intratumoral injection.
- Pathologic response [ Time Frame: 5 weeks ]Pathological response will be assessed by relative amount of viable tumor in resection specimens of the treated lesion.
- Tumor burden [ Time Frame: 5 weeks ]Change in tumor burden will be assessed per RECIST/ iRECIST guidelines for the treated lesion.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06014086
|Contact: L Mahoney||(508) firstname.lastname@example.org|
|Contact: M Spellman, MD||(508) email@example.com|
|United States, Massachusetts|
|Phio Pharmaceuticals Corp.||Not yet recruiting|
|Marlborough, Massachusetts, United States, 01752|
|Contact: L Mahoney firstname.lastname@example.org|
|Contact: M Spellman, MD email@example.com|
|United States, Ohio|
|Columbus, Ohio, United States, 43213|
|Contact: Valerie, Research Coordinator 614-336-7880|
|Study Director:||L Mahoney||Phio Pharmaceuticals Inc.|